Previous Close | 0.3650 |
Open | 0.3650 |
Bid | 0.3600 x 0 |
Ask | 0.3700 x 0 |
Day's Range | 0.3600 - 0.3650 |
52 Week Range | 0.3600 - 0.7000 |
Volume | |
Avg. Volume | 36,237 |
Market Cap | 47.438M |
Beta (5Y Monthly) | 0.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0510 |
Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Sept 02, 1999 |
1y Target Est | 1.13 |
Driven by Customer Requests, Mpox Test Control Now AvailableMISSISSAUGA, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality assessment product (“QAP™”) to support molecular diagnostic (“MDx”) testing for the Non-Variola Orthopoxvirus (“Mpox”), the cause of the cutaneous infection colloquially-known as “Monkeypox.” From traditional low-level inc
The analysts covering Microbix Biosystems Inc. ( TSE:MBX ) delivered a dose of negativity to shareholders today, by...
With a price-to-earnings (or "P/E") ratio of 31.1x Microbix Biosystems Inc. ( TSE:MBX ) may be sending very bearish...